-
1دورية أكاديمية
المؤلفون: Jimenez Balarezo, Moraima, Roldan Galvan, Elisa, Fernandez Naval, Candela, Medina-Gil, Daniel, Peralta Garzon, Soraya, Pujadas, Gemma, Hernández Buñuel, Cristina, Pagès Geli, Carlota, Gironella Mesa, Mercedes, Orti Pascual, Guillem, Barba Suñol, Pere, Pumarola Suñé, Tomàs, Cabirta Touzon, Alba, Catalá, Eva, Valentin, Mercedes, Orfao, Alberto, González, Marcos, Ruiz Camps, Isabel, Valcarcel Ferreiras, David, Bosch Albareda, Francesc, Hernández González, Manuel, Crespo Maull, Marta, Esperalba Esquerra, Juliana, Villacampa Javierre, Guillermo, Marin Niebla, Ana, Martínez Gallo, Mónica, Fox, Maria Laura, Abrisqueta, Pau, Campins Martí, Magda
المساهمون: Institut Català de la Salut, Jiménez M, Roldán E, Gironella M, Fox L, Orti G, Barba P, Valcárcel D, Bosch F, Abrisqueta P Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Fernández-Naval C, Pumarola T, Esperalba J Servei de Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Villacampa G Oncology Data Science (ODysSey) Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Martinez-Gallo M, Hernández M Servei d’Immunologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Biologia Cel·lular, Fisiologia i Immunologia, Universitat Autònoma de Barcelona, Bellaterra, Spain. Medina-Gil D, Peralta-Garzón S, Pujadas G, Hernández C, Pagès C, Crespo M Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Cabirta A, Catalá E, Valentín M, Marín-Niebla A Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Orfao A Department of Medicine and Cytometry General ServiceNucleus, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), Salamanca, Spain. González M Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC–CB16/12/00233 and Center for Cancer Research–IBMCC (USAL-CSIC), Salamanca, Spain. Campins M Servei de Medicina Preventiva i Epidemiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Ruiz-Camps I Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus
المصدر: Scientia
مصطلحات موضوعية: COVID-19 (Malaltia) - Vacunació, Immunoglobulines, Sang - Malalties, DISEASES::Neoplasms::Neoplasms by Site::Hematologic Neoplasms, DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections, PHENOMENA AND PROCESSES::Immune System Phenomena::Antibody Formation::Immunogenicity, Vaccine, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias hematológicas, ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus, FENÓMENOS Y PROCESOS::fenómenos del sistema inmunitario::formación de anticuerpos::inmunogenicidad vacunal
وصف الملف: application/pdf
العلاقة: Blood Advances;6(3); https://doi.org/10.1182/bloodadvances.2021006101Test; Jimenez M, Roldan E, Fernandez-Naval C, Villacampa G, Martinez-Gallo M, Medina-Gil D, et al. Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Adv. 2022 Feb 8;6(3):774–84.; https://hdl.handle.net/11351/8614Test; 000754263400007
-
2دورية أكاديمية
المؤلفون: Dimopoulos, Meletios, Sanz, Ramon Garcia, Lee, Hui-Peng, Trneny, Marek, Varettoni, Marzia, Opat, Stephen, D'Sa, Shirley, Owen, Roger G., Cull, Gavin, Mulligan, Stephen, Czyz, Jaroslaw, Castillo, Jorge J., Motta, Marina, Siddiqi, Tanya, Gironella Mesa, Mercedes, Granell Gorrochategui, Miquel, Talaulikar, Dipti, Zinzani, Pier Luigi, Askari, Elham, Grosicki, Sebastian, Oriol, Albert, Rule, Simon, Kloczko, Janusz, Tedeschi, Alessandra, Buske, Christian, Leblond, Veronique, Trotman, Judith, Chan, Wai Y., Michel, Jan, Schneider, Jingjing, Tan, Ziwen, Cohen, Aileen, Huang, Jane, Tam, Constantine S.
مصطلحات موضوعية: Humans, Myeloid Differentiation Factor 88/genetics, Waldenstrom Macroglobulinemia/drug therapy/genetics, Piperidines, Pyrazoles/adverse effects, Pyrimidines/adverse effects
العلاقة: https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/33284944Test/; Dimopoulos, M. et al. (2020) 'Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial.', Blood advances, 4(23), pp. 6009-6018. doi:10.1182/bloodadvances.2020003010.; https://rde.dspace-express.com/handle/11287/621842Test; Blood advances; PMC7724905
الإتاحة: https://doi.org/10.1182/bloodadvances.2020003010Test
https://rde.dspace-express.com/handle/11287/621842Test
النص الكامل